secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0000950170-24-038854
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics FY2023 net loss narrows to $10M; all-stock merger with Peak Bio
--------------------------------------------------------------------------------

- FY2023 net loss $10.0M vs $17.7M in 2022; cash $3.8M at year-end, raised $2.0M in March 2024.
- Merger as equals with Peak Bio in all-stock transaction; combined pipeline includes ADC, NEI, nomacopan, PAS-nomacopan.
- Nomacopan Phase 3 for pediatric HSCT-TMA ongoing: 10 patients treated; orphan drug and rare pediatric disease designations.
- R&D expenses $5.5M (down 43% YoY); G&A $11.4M (down 16% YoY); additional capital planned Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024038854/0000950170-24-038854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024038854/aktx-20240401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer